Pfizer Looks To Team Up With Shanghai Pharmaceutical To Co-develop And Commercialize Pfizer Products In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The world's largest pharmaceutical company Pfizer Inc. and China's second-largest distributor Shanghai Pharmaceutical Holdings Co. Ltd announced April 21 a memorandum of understanding to explore business opportunities, including the potential to jointly register, commercialize and distribute in China an innovative compound from Pfizer
You may also be interested in...
Pfizer Targets Retail Sector As China Hospitals Start To Eliminate Drug Markups
Pfizer looks to get ahead of the curve in a pilot project aimed at China’s retail pharmacies.
Pfizer Head of Preclinical Outsourcing VP Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 1 of 2)
On the way back to his old job in the U.S., after a stint in Shanghai as head of research Asia, Richard Connell says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.
Pfizer’s Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships
On the way back to his old job in the U.S., after a stint in Shanghai as head of research Asia, Richard Connell says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.